# Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

> **NCT02725866** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 216 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Paritaprevir/ritonavir/ombitasvir
- **DRUG:** Dasabuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02725866
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-05
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02725866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02725866, "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02725866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*